The Cardiologist's Mindset in the Management of Diabetes and Coronary Artery Disease: Today and Tomorrow.

Slides:



Advertisements
Similar presentations
Facts and Fiction about Type 2 Diabetes Michael L. Parchman, MD Department of Family & Community Medicine September 2004.
Advertisements

Canadian Diabetes Association 2013 Clinical Practice Guidelines Targets for Glycemic Control Chapter 8 S. Ali Imran, Rémi Rabasa-Lhoret, Stuart Ross.
Clinical implications. Burden of coronary disease 56 millions deaths worldwide in millions deaths worldwide in % due to CV disease (~ 16.
Cardiovascular Disease in Women Module V: Prognosis and Treatment Outcomes.
Session II: Glycemic control, when the lower is not the better Strict glycemic control and cardiovascular diseases Stefano Genovese Diabetologia e Malattie.
PPAR  activation Clinical evidence. Evolution of clinical evidence supporting PPAR  activation and beyond Surrogate outcomes studies Large.
Randomized Controlled Trial of Intensive Versus Conservative Glucose Control in Patients Undergoing Coronary Artery Bypass Graft Surgery: GLUCOCABG Trial.
Glycemic Control: When the Lower is Not the “Better”?
Lancet 373: , 2009 Baseline Characteristics of Participants and Study Design of Clinical Trials to Compare Intensive glucose- lowering versus.
Polypill x Aspirin Project Groups 3 and 4
Secondary prevention of a Recurrent ACS; Results from the 2004 & 2006 ACSIS Survey Perl L, Behar S, Schwartz R, Mosseri M Meir Hospital and Sheba Tel Hashomer,
An initiative of South Asian Federation of Endocrine Societies (SAFES)
Prevalence (%) estimates of diabetes (20-79 years) 2010.
Blood Glucose, Lipids, and Coronary Artery Disease: Emerging Strategies for Multimechanistic Treatment.
Copyright © 2005 American Medical Association. All rights reserved.
Diabetic Dyslipidemia in Practice
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Statin Selection in the Elderly
Diabetes and Risk of CV Outcomes
Panelists. Type 2 Diabetes, Renal Impairment, and CHD: Reducing 2 Vascular Risks With 1 Stone.
An Endocrinology Clinic in Dyslipidemia
Diabetes and Dyslipidemia
New Insights on PPAR Agonists For Cardiovascular Disease
A multicenter, double-blind, randomized study to establish the clinical benefit and safety of ezetimibe/simvastatin tablet (vytorin) vs simvastatin.
Clinical Trials in Residual Cardiovascular Risk: A Fresh Perspective
PAD Patients vs Post-ACS Patients:
Obesity and Dyslipidemia: How Would You Treat?
Clinical Advances in Type 2 Diabetes and Cardiovascular Risk
Statins and the Elderly Patient
Natural History of Atherothrombosis Finding the Right Risk-Benefit Balance.
Panelists. Unique Perspectives on the Cost Burden of Diabetes in the United States.
Early Type 2 Diabetes Mellitus: A Cardiovascular Disease
Panelists. One Size May Not Fit All: A New Aspirin Option for the High-Risk Patient.
Antiplatelet Therapy and Secondary Prevention
Incidence of CV Events in Subjects With T2D vs the Nondiabetic CAD Population
Program Goals. What Will the Emerging Basal Insulin Products Mean for My Diabetes Practice?
LDL-C Goals. The Patient With Difficult-to-Treat Hypercholesterolemia: Is Everything Under Control?
Diabetes Increases Risk of CVD
An Update on PCSK9 Inhibitors
Evaluating LDL-C Recommendations
Statins and Glucose Metabolism: Are All Agents Alike?
Growing Diabetes Pandemic Worldwide
CV Risk Management in T2DM: What Did We Learn from ADA 2016?
Exploring Statin Intolerance
Panelists. Secondary Prevention in Patients With ACS and Diabetes: How Can We Optimize Therapy?
Diabetes and Cardiovascular Disease Risk: The Hard Truth
Diabetes and Cardiovascular Disease Risk: The Hard Truth
Incidence of CV Events in Subjects With T2D vs the Nondiabetic CAD Population
Aspirin and Cardioprevention in 2018
Residual CV Risk in Patients With Dyslipidemia and Stable CAD
Advances in Hypertriglyceridemia Treatment
T2DM, CV Risk, and Modulating Risk With Glucose-Lowering Strategies
CV Risk Reduction with Diabetes Drugs -- Should Cardiologists or Diabetologists Take the Lead?
Diabetes Pandemic. The Economics of Managing Patients With Diabetes and Coronary Artery Disease: A Payer Perspective.
Panelists. Cardiovascular Risk Modulation in Diabetes: Emerging Pathways and Insights.
Pharmacotherapy for Diabetic Coronary Disease:
Managing Age-Related Clinical Issues in Hemophilia
Glucose Management and Statin Therapy
Reducing Risk for CV Outcomes
Tackling CV Risk in Type 2 Diabetes -- Gaps Between Guidelines and Clinical Practice?
Improving Adherence to Antiplatelet Therapy After an ACS Event
New Lipid-Lowering Guidelines
An Update on PCSK9 Inhibitors
Statins and Glucose Metabolism: An Endocrinology Perspective
2015 EASD In Review: CV Risk management in t2dm
Addressing Cardiovascular Events:
Glucose Management and Statin Therapy
Section overview: Hyperglycemia in ACS
Many post-MI patients are not receiving optimal therapy
Translating Data From Trial to Practice
Presentation transcript:

The Cardiologist's Mindset in the Management of Diabetes and Coronary Artery Disease: Today and Tomorrow

Panelists

CVD in the Diabetic Patient

Aspirin Evidence: Effect of Antiplatelet Treatment of Vascular Events

HOPE Study Outcomes: Events Per Patient Group

CVD Risk in Diabetic Patients Treated With Statins

Glycemia, on its Own, is a Risk Factor for Negative Cardiovascular Outcomes

Trials of More vs Less Glucose Lowering

Effects of More vs Less Intensive Glycemic Control

Accord Trial Neutral Result or Trend to Benefit Occurred

Ultimate Question

Insulin Use in the Acute Setting

DIGAMI Study: CVD Mortality Post-AMI

Common Comorbidities Associated With CVD

Common Glucose-Lowering Drugs

ACS in the Emergency Department

Perception Issues

ACCORD Trial Takeaways

Gaps in Knowledge and Practice

Final Thoughts

Abbreviations

Abbreviations (cont)

References

References (cont)

References (cont)